(ELV) Elevance Health - Overview
Sector: Healthcare | Industry: Healthcare Plans | Exchange: NYSE (USA) | Market Cap: 85.577m USD | Total Return: 4.8% in 12m
Avg Turnover: 624M
EPS Trend: -42.0%
Qual. Beats: 1
Rev. Trend: 97.1%
Qual. Beats: 8
Warnings
No concerns identified
Tailwinds
Supp Ema8, Supp Ema20
Elevance Health, Inc. (ELV) is a major U.S. health benefits provider operating through four primary segments: Health Benefits, CarelonRx, Carelon Services, and Corporate & Other. The company provides medical, pharmacy, dental, and vision insurance products to individual, employer, Medicare, and Medicaid members. Beyond traditional insurance, the company manages clinical data through its HealthOS platform and provides specialized services in behavioral health, palliative care, and payment integrity.
Operating as a Managed Care Organization (MCO), Elevance Health utilizes a diversified business model that integrates insurance risk-bearing with fee-based administrative services. This structure is common in the Managed Health Care sector, where companies increasingly expand into pharmacy benefit management (PBM) and direct care delivery to capture more value across the healthcare continuum. The company holds significant market share through its licensing of the Anthem Blue Cross and Blue Shield brands in multiple states.
Investors can evaluate the companys long-term valuation metrics and growth drivers on ValueRay. Since rebranding from Anthem in 2022, the company has focused on scaling its Carelon brand to provide healthcare services to both its own members and external third-party payers.
- Medicaid redeterminations and enrollment shifts impact government business revenue growth
- Carelon services expansion drives margin improvement through internal pharmacy benefit management
- Medicare Advantage utilization rates and federal reimbursement levels pressure operational profitability
- Commercial membership growth in employer-sponsored plans stabilizes fee-based administrative income
| Net Income: 5.24b TTM > 0 and > 6% of Revenue |
| FCF/TA: 0.05 > 0.02 and ΔFCF/TA 2.06 > 1.0 |
| NWC/Revenue: 10.84% < 20% (prev 1.51%; Δ 9.33% < -1%) |
| CFO/TA 0.06 > 3% & CFO 7.61b > Net Income 5.24b |
| Net Debt (-3.72b) to EBITDA (8.92b): -0.42 < 3 |
| Current Ratio: 1.48 > 1.5 & < 3 |
| Outstanding Shares: last quarter (220.4m) vs 12m ago -2.99% < -2% |
| Gross Margin: 23.16% > 18% (prev 0.28%; Δ 2.29k% > 0.5%) |
| Asset Turnover: 163.2% > 50% (prev 153.0%; Δ 10.28% > 0%) |
| Interest Coverage Ratio: 5.39 > 6 (EBITDA TTM 8.92b / Interest Expense TTM 1.42b) |
| A: 0.17 (Total Current Assets 67.0b - Total Current Liabilities 45.3b) / Total Assets 126b |
| B: 0.28 (Retained Earnings 35.8b / Total Assets 126b) |
| C: 0.06 (EBIT TTM 7.63b / Avg Total Assets 123b) |
| D: 0.43 (Book Value of Equity 35.1b / Total Liabilities 81.8b) |
| Altman-Z'' = 2.93 = A |
| DSRI: 1.33 (Receivables 22.8b/15.6b, Revenue 200b/183b) |
| GMI: 1.20 (GM 23.16% / 27.74%) |
| AQI: 0.56 (AQ_t 0.43 / AQ_t-1 0.77) |
| SGI: 1.09 (Revenue 200b / 183b) |
| TATA: -0.02 (NI 5.24b - CFO 7.61b) / TA 126b) |
| Beneish M = -2.78 (Cap -4..+1) = A |
As of May 24, 2026, the stock is trading at USD 389.82 with a total of 1,253,728 shares traded.
Over the past week, the price has changed by +0.51%,
over one month by +20.26%,
over three months by +18.24% and
over the past year by +4.84%.
Elevance Health has received a consensus analysts rating of 4.41. Therefore, it is recommended to buy ELV.
- StrongBuy: 13
- Buy: 5
- Hold: 4
- Sell: 0
- StrongSell: 0
| Analysts Target Price | 389 | -0.2% |
P/E Forward = 14.771
P/S = 0.427
P/B = 1.8701
P/EG = 1.4479
Revenue TTM = 200b USD
EBIT TTM = 7.63b USD
EBITDA TTM = 8.92b USD
Long Term Debt = 30.8b USD (from longTermDebt, last quarter)
Short Term Debt = 724.0m USD (from shortTermDebt, last quarter)
Debt = 31.8b USD (from shortLongTermDebtTotal, last quarter)
Net Debt = -3.72b USD (calculated: Debt 31.8b - CCE 35.6b)
Enterprise Value = 81.9b USD (85.6b + Debt 31.8b - CCE 35.6b)
Interest Coverage Ratio = 5.39 (Ebit TTM 7.63b / Interest Expense TTM 1.42b)
EV/FCF = 12.69x (Enterprise Value 81.9b / FCF TTM 6.45b)
FCF Yield = 7.88% (FCF TTM 6.45b / Enterprise Value 81.9b)
FCF Margin = 3.22% (FCF TTM 6.45b / Revenue TTM 200b)
Net Margin = 2.62% (Net Income TTM 5.24b / Revenue TTM 200b)
Gross Margin = 23.16% ((Revenue TTM 200b - Cost of Revenue TTM 154b) / Revenue TTM)
Gross Margin QoQ = 18.14% (prev 23.48%)
Tobins Q-Ratio = 0.65 (Enterprise Value 81.9b / Total Assets 126b)
Interest Expense / Debt = 4.44% (Interest Expense 1.42b / Debt 31.8b)
Taxrate = 23.61% (544.0m / 2.30b)
NOPAT = 5.83b (EBIT 7.63b * (1 - 23.61%))
Current Ratio = 1.48 (Total Current Assets 67.0b / Total Current Liabilities 45.3b)
Debt / Equity = 0.73 (Debt 31.8b / totalStockholderEquity, last quarter 43.9b)
Debt / EBITDA = -0.42 (Net Debt -3.72b / EBITDA 8.92b)
Debt / FCF = -0.58 (Net Debt -3.72b / FCF TTM 6.45b)
Total Stockholder Equity = 43.9b (last 4 quarters mean from totalStockholderEquity)
RoA = 4.27% (Net Income 5.24b / Total Assets 126b)
RoE = 11.95% (Net Income TTM 5.24b / Total Stockholder Equity 43.9b)
RoCE = 10.23% (EBIT 7.63b / Capital Employed (Equity 43.9b + L.T.Debt 30.8b))
RoIC = 7.18% (NOPAT 5.83b / Invested Capital 81.2b)
WACC = 5.60% (E(85.6b)/V(117b) * Re(6.42%) + D(31.8b)/V(117b) * Rd(4.44%) * (1-Tc(0.24)))
Discount Rate = 6.42% (= CAPM, Blume Beta Adj.)
Shares (quarterly) Correlation: -98.88 | Cagr: -2.96%
[DCF] Terminal Value 77.97% ; FCFF base≈5.34b ; Y1≈6.12b ; Y5≈9.01b
[DCF] Fair Price = 641.4 (EV 136b - Net Debt -3.72b = Equity 139b / Shares 217.2m; r=8.35% [WACC [floored]]; 5y FCF grow 15.0% → 2.50% )
EPS Correlation: -42.02 | EPS CAGR: -2.44% | SUE: 2.66 | # QB: 1
Revenue Correlation: 97.10 | Revenue CAGR: 7.68% | SUE: 2.70 | # QB: 8
EPS current Quarter (2026-06-30): EPS=6.20 | Chg30d=-6.06% | Revisions=+0% | Analysts=19
EPS next Quarter (2026-09-30): EPS=5.10 | Chg30d=-5.69% | Revisions=-55% | Analysts=19
EPS current Year (2026-12-31): EPS=26.91 | Chg30d=+3.64% | Revisions=+76% | GrowthEPS=-11.2% | GrowthRev=-1.7%
EPS next Year (2027-12-31): EPS=29.25 | Chg30d=-0.45% | Revisions=+64% | GrowthEPS=+8.7% | GrowthRev=+2.2%
[Analyst] Revisions Ratio: +76%